WARSAW, Ind., Jan. 25, 2019 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global leader in
musculoskeletal healthcare, today announced U.S. Food and Drug
Administration 510(k) clearance of the ROSA® Knee System
for robotically-assisted total knee replacement surgeries. ROSA
Knee features 3D pre-operative planning tools and real-time,
intraoperative data on soft-tissue and bone anatomy designed to
improve bone cut accuracy and range of motion gap analysis to
potentially improve flexion and restoration of natural joint
movement.
"Complementing the skill and expertise of the surgeon with ROSA
Knee's robotically-assisted technologies can improve accuracy,
precision and consistency, which can improve patient satisfaction,
clinical outcomes and efficiency," said Christopher J. Cannova, M.D., Washington Joint
Institute at OrthoBethesda. "ROSA Knee functions as a surgical
assistant that gives me the tools and real-time data to perform
bone cuts with greater precision and improve patient-specific
soft-tissue balancing and implant alignment, without losing my feel
for a natural fit and flexion."
ROSA Knee leverages Zimmer Biomet's ROSA Robotics platform,
which includes ROSA Brain for neurosurgical procedures.
"We are excited for the launch of ROSA Knee, which brings
together Zimmer Biomet's robotics technology with our
industry-leading Knee implants to help surgeons personalize
surgical procedures for their patients," said Ivan Tornos, Group
President, Orthopedics. "Zimmer Biomet is committed to leading the
industry in bringing differentiated and holistic solutions to
market that address the needs of our customers and improve patient
outcomes."
About ROSA Knee
ROSA Knee is a robotically-assisted surgical system designed to
help surgeons in performing total knee replacement surgery with
features to assist with bone resections as well as assessing the
state of soft tissues to facilitate implant positioning
intraoperatively. The system provides a continuum of data analysis
to assist in complex decision-making and enables surgeons to use
computer and software technology to control and move surgical
instruments, allowing for greater precision and flexibility during
procedures. ROSA Knee features the Company's proprietary X-Atlas™
imaging protocol—which provides x-ray based preoperative imaging to
create a 3D model and plan of a patient's bone anatomy—and
intraoperative, real-time mapping of a patient's anatomy and motion
to help surgeons personalize procedures and improve outcomes.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global
leader in musculoskeletal healthcare. We design, manufacture and
market orthopaedic reconstructive products; sports medicine,
biologics, extremities and trauma products; office-based
technologies; spine, craniomaxillofacial and thoracic products;
dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at
www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This release contains forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include,
but are not limited to, statements concerning Zimmer Biomet's
expectations, plans, prospects, and product and service offerings,
including new product launches and potential clinical successes.
Such statements are based upon the current beliefs and expectations
of management and are subject to significant risks, uncertainties
and changes in circumstances that could cause actual outcomes and
results to differ materially. For a list and description of some of
such risks and uncertainties, see Zimmer Biomet's periodic reports
filed with the U.S. Securities and Exchange Commission (SEC). These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in Zimmer Biomet's filings with the SEC. Forward-looking statements
speak only as of the date made. Zimmer Biomet disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Readers of this release are cautioned not to rely on
these forward-looking statements, since there can be no assurance
that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking
statements contained in this release.
ZBH-Corp
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zimmer-biomet-receives-fda-clearance-for-rosa-knee-system-for-robotically-assisted-surgeries-300784240.html
SOURCE Zimmer Biomet Holdings, Inc.